| abstract |
The invention relates to a composition for the prevention or treatment of diabetes, diabetic obesity or complications of diabetes containing an oxyntomodulin analog conjugate as an active ingredient, as well as a method for treating diabetes, diabetic obesity or complications of diabetes, comprising administering to a subject a pharmaceutically effective amount of an oxyntomodulin analog conjugate. An analogue of oxyntomodulin has a high ability to activate the GLP-1 receptor (glucagon-like peptide-1) and glucagon receptor compared to native oxyntomodulin, induces the development of beta cells and increases insulin secretion, thereby reducing blood glucose levels, which were increased due to high calorie a diet high in fat. The oxyntomodulin analog induces a decrease in body weight and a decrease in food intake with an increase in insulin sensitivity and allows blood glucose levels that are not controlled due to insulin resistance to be maintained at normal levels. Therefore, the oxyntomodulin analog conjugate can be effectively used to prevent or treat diabetes and related diseases. |